Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3260 | Placebo microcrystalline methylcellulose Wiki | 1.00 |
drug3253 | Placebo for liposomed resveratrol and curcumin Wiki | 1.00 |
drug2350 | Liposomed polyphenols resveratrol and curcumin Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D000690 | Amyotrophic Lateral Sclerosis NIH | 0.50 |
D016472 | Motor Neuron Disease NIH | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.50 |
HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.50 |
Navigate: Correlations HPO
There is one clinical trial.
Amyotrophic lateral sclerosis (ALS) is a disease of an inflammatory nature, which causes progressive muscle weakness associated with cognitive and behavioural disorders. Pathogenically, it is characterised by loss of oxidative control, excitotoxicity due to excess glutamate and intestinal dysbiosis. In the absence of curative treatment, the aim of the study is to assess the impact at a clinical level of the combination of liposomed polyphenols to improve their effectiveness, with the drug Dutasteride which shows great anti-ALS properties by Molecular Topology methodology. A prospective, longitudinal, mixed, analytical, experimental and double-blind study is proposed, with a population sample of 100 patients distributed randomly in 50 patients in the intervention group who will receive treatment for 6 months, and 50 patients in the control group who will receive a placebo for the same period. The assessment will be at time 0, and at 3 months and 6 months after treatment, with functional, cognitive and behavioural tests, and of the state of inflammation and oxidation; and at time 0 and 6 months, of the intestinal microbiota.
Description: Maximum value: 48 points; Means better outcome motor variables Minimum value: 0 points
Measure: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale associated with ALS Time: Time 0Description: Maximum value: 48 points; Means better outcome motor variables Minimum value: 0 points
Measure: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale associated with ALS Time: 3 monthsDescription: Maximum value: 48 points; Means better outcome motor variables Minimum value: 0 points
Measure: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale associated with ALS Time: 6 monthsDescription: Motor Variables
Measure: Electromyography Time: Time 0Description: Motor Variables
Measure: Electromyography Time: 3 monthsDescription: Motor Variables
Measure: Electromyography Time: 6 monthsDescription: Motor Variables
Measure: Measurement of forced vital capacity Time: Time 0Description: Motor Variables
Measure: Measurement of forced vital capacity Time: 3 monthsDescription: Motor Variables
Measure: Measurement of forced vital capacity Time: 6 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma IL-6 and TNF-alpha. Time: Time 0Description: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma IL-6 and TNF-alpha. Time: 3 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma IL-6 and TNF-alpha. Time: 6 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma PCR. Time: Time 0Description: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma PCR. Time: 3 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma PCR. Time: 6 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma haptoglobin. Time: Time 0Description: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma haptoglobin. Time: 3 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma haptoglobin. Time: 6 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of TEAC (oxidation). Time: Time 0Description: Variables related to inflammation and oxidation
Measure: Quantitative measurement of TEAC (oxidation). Time: 3 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of TEAC (oxidation). Time: 6 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma 8-oxoG. Time: Time 0Description: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma 8-oxoG. Time: 3 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma 8-oxoG. Time: 6 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma MDA. Time: Time 0Description: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma MDA. Time: 3 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma MDA. Time: 6 monthsDescription: Variable for cognitive and behavioural assesment Maximum value: 136 points; Means better outcome Minimum value: 0 points Includes a behavioural test to interview the care provider
Measure: Edinburgh Cognitive and Behavioral ALS Screen Time: Time 0Description: Variable for cognitive and behavioural assesment Maximum value: 136 points; Means better outcome Minimum value: 0 points Includes a behavioural test to interview the care provider
Measure: Edinburgh Cognitive and Behavioral ALS Screen Time: 3 monthsDescription: Variable for cognitive and behavioural assesment Maximum value: 136 points; Means better outcome Minimum value: 0 points Includes a behavioural test to interview the care provider
Measure: Edinburgh Cognitive and Behavioral ALS Screen Time: 6 monthsDescription: Variable for cognitive and behavioural assesment Maximum value: 18 points; Means better outcome 16-15 points means frontosubcortical deficit 13-12 points means frontosubcortical dementia Minimum value: 0 points Includes a behavioural test to interview the care provider
Measure: Frontal Assessment Battery Time: Time 0Description: Variable for cognitive and behavioural assesment Maximum value: 18 points; Means better outcome 16-15 points means frontosubcortical deficit 13-12 points means frontosubcortical dementia Minimum value: 0 points Includes a behavioural test to interview the care provider
Measure: Frontal Assessment Battery Time: 3 monthsDescription: Variable for cognitive and behavioural assesment Maximum value: 18 points; Means better outcome 16-15 points means frontosubcortical deficit 13-12 points means frontosubcortical dementia Minimum value: 0 points Includes a behavioural test to interview the care provider
Measure: Frontal Assessment Battery Time: 6 monthsDescription: A Clinical Intestinal Microbiome will be performed, which is an analysis of the bacterial microbiota present in the intestine, from a stool sample.
Measure: Variables related to the microbiota Time: Time 0Description: A Clinical Intestinal Microbiome will be performed, which is an analysis of the bacterial microbiota present in the intestine, from a stool sample.
Measure: Variables related to the microbiota Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports